Regeneron Pharmaceuticals, Inc.

Medimmune Limited

Gregory P Geba

John Davis

Nestor Molfino

Jennifer Maloney

Joseph M Parker

Catherine Stehman Breen

Haitao Gao, Sr

David L Gossage

Paula Dakin

Deepak B Khatry

Stephen DiMartino

A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

Pharmaceutical composition for safe and effective treatment of knee and/or hip pain

The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy.

Methods of diagnosing and treating pulmonary diseases or disorders

Growing community of inventors

Sparta, NJ, United States of America

Gregory P Geba